Systematix

Institutional Equities

Aptus Value Housing Finance

04 November 2023

In-line operating performance; Guidance maintained

APTUS Q2FY24 operational performance was in line with our estimates. NII / OP at Rs 2.3bn / Rs 1.9bn registered a healthy growth of 20% YoY (7.7% QoQ) / 18% YoY (5.0% in QoQ). Operating expenses increased 20.3% QoQ due to the increase in employee count and branch additions. With credit cost at 0.3%, PAT was also inline with our estimates at Rs 1.5bn. AUM and disbursement growth was strong at 28% YoY / 7% QoQ and 23% YoY / 15.3% QoQ driven by healthy demand and branch expansion. NIMs (calc) increased by 17bps QoQ driven by 50bps increase in yields (calc), even as cost of funds increased by 33bps QoQ. Asset quality saw an improvement, with GS3/NS3 marginally down by 10bps/8bps to 1.2%/0.9%. We estimate a 30% CAGR in APTUS AUM which will deliver 21% CAGR in earnings over FY23-25E resulting in RoA / RoE of 6.8% / 18.4% in FY25. Key risks: Inflation pressure might impact the demand for home loans.

Key result highlights

- APTUS 2QFY24 operational performance was in line with our estimates. NII / OP at Rs 2.3bn / Rs 2.0bn registered a healthy growth of 20% YoY (7.7% QoQ) / 18% YoY (5.0% in QoQ) led by AUM growth of 28%yoy and 17bps qoq expansion in NIMs to 12.4%. With 0.3% credit cost (around guided range of 0.25%) PAT came in line with our estimates at Rs 1.5bn. Spreads were largely steady at 8.8%.
- AUM growth was strong at 28% YoY / 7% QoQ. HL segment (59% of AUM) grew by 30.4% YoY (6.8% QoQ), Quasi Home loans (LAP) (17% of AUM) AUM grew by 45.3% YoY (13.4% QoQ), Small business loans (20% of AUM) grew by 28.2% YoY (1.7% QoQ), while Insurance and top up loan (4% of AUM) de-grew 27% YoY (7% QoQ). Disbursements growth picked up with a growth of 15.3% QoQ (23% YoY).
- Reported Spreads contracted by 6bps QoQ to 8.8% mainly due to 11bps increase
 in cost of borrowings. NIMs (calc) increased by 17bps QoQ driven by 50bps
 increase in yields (calc). Provisions jumped 2x QoQ at Rs 56mn (on expected lines)
 resulting in credit cost of 0.3% vs 0.1% in 1Q.
- Operating expenses increased 20.3% QoQ (vs avg >40% YoY in past few quarters) led by 21.4% and 17.5% QoQ rise in employee cost and other expenses. Higher employee costs and other expenses was on account of increase in number of employees and branches. Opex to AUM ratio decreased to 2.9% in Q2FY24 from 3.1% in Q2FY23 (2.6% in Q1FY24).
- Asset quality saw an improvement, with GS3/NS3 marginally down by 10bps/8bps to 1.2%/0.9%. PCR on Stage 3 assets stood stable at ~25% in Q2. 30+dpd improved by 28bp QoQ to 5.9%. ECL coverage was steady QoQ at 1.06%, in line with management guidance.

Valuation & recommendation

APTUS reported in-line earnings aided by strong AUM growth, NIMs expansion and improvement in asset quality. We maintain our earnings estimates for FY24/25 as disbursement is expected to maintain a steady run rate of 15% QoQ in H2 and there are levers for margins expansion. Hence, we continue to remain positive on APTUS core strengths and underwriting practices, which has demonstrated healthy earnings growth and asset quality. AUM growth guidance maintained at 30%+ YoY for FY24. We have a buy rating on the stock with a target price of Rs. 350 valuing the company at ~4x FY25E book value.

RESULT UPDATE Sector: NBFCs Rating: BUY CMP: 294 Target Price: Rs 350

CIVIF . 234	raiget Frice. No 330
Stock Info	
Sensex/Nifty	64,482/19,262
Bloomberg	APTUS IN
Equity shares	498 mn
52-wk High/Low	338/234
Face value	Rs 2
M-Cap	Rs 146bn/USD1.8bn
3-m Avg volume	USD 2.0mn


		_
Financia	l Snapshot	t (Rs mn)

rinanciai shapshot (ks iiiii)								
FY23 FY24E FY25E	Y/E March							
7,825 9,510 11,608	NII							
6,878 8,271 10,003	PPP							
5,030 6,185 7,424	PAT							
10.1 12.4 14.9	EPS (Rs)							
35.9 23.0 20.0	EPS Gr. (%)							
67 76 86	BV/Sh (Rs)							
	Ratios							
13.1 12.2 11.5	NIM (%)							
19.4 20.4 21.7	C/I ratio (%)							
7.8 7.4 6.8	RoA (%)							
16.1 17.4 18.4	RoE (%)							
39.6 30.0 30.0	Payout (%)							
	Valuations							
29.1 23.7 19.7	P/E (x)							
4.4 3.9 3.4	P/BV (x)							
1.4 1.3 1.5	Div. Yield (%)							
39.6 30.0 3 29.1 23.7 1 4.4 3.9	Payout (%) Valuations P/E (x) P/BV (x)							

Shareholding pattern (%)

	Mar-22	Jun-23	Sep-23
Promoter	62.2	62.2	62.1
FII	14.1	14.2	14.8
DII	2.6	2.9	2.8
Others	21.2	20.7	20.3

Stock Performance (1-year)



Pradeep Agrawal

pradeepagrawal@systematixgroup.in +91 22 6704 8024

Pravin Mule

pravinmule@systematixgroup.in

Ronak Dhruv

ronakdhruv@systematixgroup.in

Systematix Research is also available on Bloomberg SSSL <Go>, Thomson & Reuters

Management commentary

Business:

- Focus continues on low & mid-income segment in tier 3 & 4 cities.
- Disbursement growth will be driven by deeper penetration in existing markets & expansion in new markets.
- Strong on ground demand will aid in sustainable earnings growth.
- Disbursement break-up: HL Rs ~5000mn, NBFC: Rs ~2500mn.
- There was some attrition in TN at branch manager level. Overall attrition rate lower at senior / mid-level management.
- BT out run rate to be maintained at 2.5%.

OPEX:

- During H1 added 19 branches. First branch opened in Maharashtra (Nanded) in 3Q.
- Opex was higher during the quarter mainly due to 300-350 employee addition and addition in branch network. Management indicated that every year 30-35 branches will be added.

Margins:

- Margin expansion will be aided by borrowings from NHB (sanction limit is Rs 3bn and available at 0.5% lesser than market rate) and rate hike of ~50bps taken in Sep'23.
- Incremental cost of borrowings HL: + 10bps (8.25 to 8.35%), NBFC loans: +35-50bps. CoF likely to be 8.4-8.5% levels in FY24.

Asset Quality:

- Portfolio in Stage 2 to come down led by healthy collections.
- Most of the loans are secured against SORP hence see the bounce rate at ~15% and likely to be maintained at current levels.

Guidance:

- AUM growth guidance maintained at 30%+ YoY.
- Disbursements growth will be maintained at 15% QoQ in H2.

Exhibit 1: Quarterly performance

(Rs mn)	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	YoY (%)	QoQ (%)
Net Interest Income	1,906	2,002	2,130	2,121	2,285	19.9	7.7
Other Income	196	175	178	181	198	1.2	9.8
Net Income	2,102	2,176	2,307	2,301	2,483	18.1	7.9
Total Operating Expenses	446	414	466	442	532	19.4	20.3
As % Of Net Income	21.2	19.0	20.2	19.2	21.4	23bps	221bps
Employee Expenses	330	309	354	324	393	19.4	21.4
As % Of Net Income	15.7	14.2	15.3	14.1	15.8	17bps	176bps
Other Expenses	116	105	112	118	138	19.4	17.5
As % Of Net Income	5.5	4.8	4.9	5.1	5.6	6bps	45bps
Operating Profit	1,657	1,762	1,841	1,859	1,951	17.8	5.0
As % Of Net Income	78.8	81.0	79.8	80.8	78.6	(23bps)	(221bps)
Provisions	91	78	78	25	56	-38.7	123.3
PBT	1,566	1,684	1,764	1,834	1,896	21.1	3.3
Total Tax	333	429	411	412	415	24.8	0.9
Reported PAT	1,233	1,256	1,353	1,423	1,480	20.0	4.1
Adjusted PAT	1,233	1,256	1,353	1,423	1,480	20.0	4.1

Yield Analysis (%)	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	YoY (%)	QoQ (%)
Yield on AUM (calc)	18.0	18.1	17.8	17.1	17.6	(35bps)	50bps
Cost of funds (calc)	4.7	5.0	4.8	4.9	5.2	55bps	33bps
Cost of borrowing (calc)	7.7	7.9	7.9	8.6	9.1	143bps	56bps
NIMs (calc)	13.3	13.1	13.1	12.2	12.4	(91bps)	17bps
Yields (reported)	16.9	16.9	17.0	17.2	17.2	35bps	5bps
Cost of borrowing (reported)	7.7	7.9	8.1	8.3	8.4	71bps	11bps
NIMs (reported)	9.2	9.0	8.9	8.9	8.8	(36bps)	(6bps)

Asset quality (IndAs)	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	YoY (%)	QoQ (%)
Gross Stage 3	869	911	777	922	906	4.2	-1.8
Net Stage 3	652	683	583	692	680	4.2	-1.8
Gross Stage 3 (%)	1.5	1.4	1.2	1.3	1.2	(27bps)	(10bps)
Net Stage 3 (%)	1.1	1.1	0.9	1.0	0.9	(21bps)	(8bps)
Net NPAs/Net worth (%)	2.1	2.1	1.7	2.0	1.9	(13bps)	(13bps)
Provision cover (%)	25.0	25.0	25.0	25.0	25.0	(bps)	(bps)

AUM (Rs mn)	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	YoY (%)	QoQ (%)	% of total
Home loans	34,406	37,211	39,080	42,026	44,864	30.4	6.8	59
Quasi home (LAP)	8,898	9,461	10,107	11,397	12,927	45.3	13.4	17
Insurance loan	1,780	1,892	2,021	1,425	1,521	-14.5	6.8	2
Top up loan	2,373	2,523	2,021	1,425	1,521	-35.9	6.8	2
Small business loan	11,864	12,614	14,150	14,958	15,208	28.2	1.7	20
Total AUM	59,320	63,070	67,380	71,230	76,040	28.2	6.8	100


(Rs mn)	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	YoY (%)	QoQ (%)
Borrowing	37,030	36,590	37,790	41,340	40,044	8.1	-3.1
Break up %							
Banks	64	62	60	60	62	(200bps)	200bps
NHB	21	23	26	28	26	500bps	(200bps)
NCD	5	4	4	3	5	0	200bps
Others	10	11	10	9	7	(300bps)	(200bps)



(Rs bn) (%) 100 35 31 30 29 28 75 26 50 18 25 9 0 0 Sep-22 Dec-22 Mar-23 Jun-23 Sep-23

YoY (RHS)

Exhibit 3: ...led by healthy disbursements



Source: Company, Systematix Institutional Research

Source: Company, Systematix Institutional Research

Exhibit 4: Share of housing loans steady at 59%

AUM





Exhibit 5: Well diversified borrowing mix



Source: Company, Systematix Institutional Research

Source: Company, Systematix Institutional Research

Exhibit 6: Spreads largely maintained on sequential basis





Exhibit 7: ...similarly NIMs stood largely steady



Source: Company, Systematix Institutional Research

700

Sep-22

Exhibit 8: ~10bps QoQ improvement in GS3 ratio Exhibit 9: Credit cost was higher on expected lines (Rs mn) (%) 950 1.8 8.0 1.5 1.4 0.63 888 1.4 1.2 0.6 0.51 0.48 825 0.9 0.4 0.30 0.14 763 0.5 0.2

Source: Company, Systematix Institutional Research

Dec-22

Gross stage 3

Mar-23

Jun-23

Gross stage 3 ratio (RHS)

Source: Company, Systematix Institutional Research

Dec-22

Mar-23

Credit cost

Jun-23

Sep-23

Exhibit 10: Change in estimates

0.0

Sep-23

0.0

Sep-22

(Rs bn)	Old Estimates		New Es	timates	% Change		
	FY24	FY25	FY24	FY25	FY24	FY25	
NII	9.5	11.6	9.5	11.6	0.0	0.0	
Operating Profit	8.3	10.0	8.3	10.0	0.0	0.0	
PAT	6.2	7.4	6.2	7.4	0.0	0.0	
BV	76	86	76	86	0.0	0.0	
EPS	12	15	12	15	0.0	0.0	

FINANCIALS

Profit & Loss Statement

YE: Mar (Rs mn)	FY21	FY22	FY23	FY24E	FY25E
Net interest income	4,203	5,831	7,825	9,510	11,608
Other income	314	485	706	887	1,169
Net Income	4,517	6,316	8,531	10,397	12,777
Operating expenses	1,008	1,171	1,652	2,126	2,774
Preprovision profit	3,509	5,145	6,878	8,271	10,003
Provisions	58	345	341	233	355
Profit before tax	3,451	4,800	6,537	8,038	9,649
Tax	781	1,099	1,507	1,853	2,224
Tax rate	22.6	22.9	23.1	23.1	23.1
Reported Profit after tax	2,669	3,701	5,030	6,185	7,424

Source: Company, Systematix Institutional Research

Balance Sheet

YE: Mar (Rs mn)	FY21	FY22	FY23	FY24E	FY25E
Equity	949	994	996	996	996
Reserves	18,845	28,168	32,397	36,727	41,924
Net worth	19,795	29,162	33,393	37,723	42,920
Borrowings	25,080	27,206	37,861	56,412	79,541
Others	327	473	507	923	1,519
Total liabilities	45,202	56,840	71,761	95,059	1,23,981
Cash	4,378	4,459	4,600	6,160	8,032
Investments	528	1,017	515	880	1,147
Loans	39,898	50,787	65,921	87,071	1,13,566
Others	303	457	572	747	974
Total assets	45,202	56,840	71,761	95,059	1,23,981

Source: Company, Systematix Institutional Research

Dupont (as % of Average Assets)

YE: Mar	FY21	FY22	FY23	FY24E	FY25E
Interest Income	15.2	15.5	16.5	16.2	16.0
Interest Expense	5.0	4.1	4.3	4.8	5.4
Net Interest Income	10.2	11.4	12.2	11.4	10.6
Other income total	0.8	1.0	1.1	1.1	1.1
Net Income total	10.9	12.4	13.3	12.5	11.7
Operating expenses total	2.4	2.3	2.6	2.55	2.53
Preprovision profit	8.5	10.1	10.7	9.9	9.1
Provisions	0.1	0.7	0.5	0.3	0.3
Profit before tax and exce. items 8.3		9.4	10.2	9.6	8.8
Profit before tax	8.3	9.4	10.2	9.6	8.8
Tax total	1.9	2.2	2.3	2.2	2.0
Profit after tax	6.5	7.3	7.8	7.4	6.8

Source: Company, Systematix Institutional Research

Key Ratios

-					
YE: Mar	FY21	FY22	FY23	FY24E	FY25E
Yield on portfolio	17.6	17.5	18.1	17.7	17.5
cost of borrowings	9.1	8.0	8.5	8.6	8.8
Interest Spread	8.5	9.5	9.7	9.2	8.8
NIM (on AUM)	11.6	12.6	13.1	12.2	11.5
Cost/ Income (%)	22.3	18.5	19.4	20.4	21.7
Credit cost (%)	0.1	0.7	0.5	0.3	0.3
RoA(%)	6.5	7.3	7.8	7.4	6.8
RoE(%)	14.5	15.1	16.1	17.4	18.4
Leverage (x)	2.2	2.1	2.1	2.3	2.7
Tier I (%)	73.8	85.4	76.6	66.3	58.6
CAR (%)	73.6	85.6	77.4	66.9	59.1
Gross NPA (%)	0.7	1.2	1.2	1.2	1.1
Net NPA (%)	0.5	0.9	0.9	0.9	0.8
Provision coverage (%)	27.5	25.3	25.0	25.0	25.0

Source: Company, Systematix Institutional Research

Growth

YE: Mar (%)	FY21	FY22	FY23	FY24E	FY25E
Net interest income	40.1	38.7	34.2	21.5	22.1
Net Income total	33.4	39.8	35.1	21.9	22.9
Preprovision profit	40.3	46.6	33.7	20.2	20.9
Profit before tax	39.5	39.1	36.2	23.0	20.0
Profit after tax	26.5	38.7	35.9	23.0	20.0
Loan	28.0	27.3	29.8	32.1	30.4
Disbursement	1.4	26.4	45.9	34.0	30.0
AUM	27.8	27.4	30.1	30.6	30.4

Source: Company, Systematix Institutional Research

Valuation ratios

YE: Mar	FY21	FY22	FY23	FY24E	FY25E
FDEPS (Rs)	5.4	7.4	10.1	12.4	14.9
PER (x)	54.9	39.6	29.1	23.7	19.7
Book value (Rs)	39.7	58.6	67.1	75.7	86.2
P/BV (Rs)	7.4	5.0	4.4	3.9	3.4
Adjusted book value (Rs)	39.3	57.6	65.9	74.2	84.3
P/ABV (Rs)	7.5	5.1	4.5	4.0	3.5
P/PPP (x)	41.7	28.5	21.3	17.7	14.6
Dividend yield (%)	0.0	0.0	1.4	1.3	1.5

Institutional Equities Team

Nikhil Khandelwal	Managing Director	+91-22-6704 8001	nikhil@systematixgroup.in
Equity Research			
Analysts	Industry Sectors	Desk-Phone	E-mail
Dhananjay Sinha	Co Head of Equities & Head of Research - Strategy & Economics	+91-22-6704 8095	dhananjaysinha@systematixgroup.in
Ashish Poddar	Consumer Durables, EMS, Building Materials, Small-Mid Caps	+91-22-6704 8039	ashishpoddar@systematixgroup.in
Himanshu Nayyar	Consumer Staples & Discretionary	+91-22-6704 8079	himanshunayyar@systematixgroup.in
Manjith Nair	Banking, Insurance	+91-22-6704 8065	manjithnair@systematixgroup.in
Pradeep Agrawal	NBFCs & Diversified Financials	+91-22-6704 8024	pradeepagrawal@systematixgroup.in
Pratik Tholiya	Specialty & Agro Chem, Fertilisers, Sugar, Textiles and Select Midcaps	+91-22-6704 8028	pratiktholiya@systematixgroup.in
Sameer Pardikar	IT & ITES	+91-22-6704 8041	sameerpardikar@systematixgroup.in
Sudeep Anand	Oil & Gas, Logistics, Cement, Wagons	+91-22-6704 8085	sudeepanand@systematixgroup.in
Vishal Manchanda	Pharmaceuticals and Healthcare	+91-22-6704 8064	vishalmanchanda@systematixgroup.in
Chetan Mahadik	Consumer Staples & Discretionary	+91-22-6704 8091	chetanmahadik@systematixgroup.in
Devanshi Kamdar	IT & ITES	+91-22-6704 8098	devanshikamdar@systematixgroup.in
Iennisa Popat	Oil & Gas, Logistics, Cement, Wagons	+91-22-6704 8066	jennisapopat@systematixgroup.in
Kalash Jain	Consumer Durables, EMS, Building Materials, Small-Mid Caps	+91-22-6704 8038	kalashjain@systematixgroup.in
Nirali Chheda	Banking, Insurance	+91-22-6704 8019	niralichheda@systematixgroup.in
Pashmi Chheda	Banking, Insurance	+91-22-6704 8063	pashmichheda@systematixgroup.in
Pranay Shah	Consumer Durables, EMS, Building Materials, Small-Mid Caps	+91-22-6704 8017	pranayshah@systematixgroup.in
Pratik Oza	Midcaps	+91-22-6704 8036	pratikoza@systematixgroup.in
Pravin Mule	NBFCs & Diversified Financials	+91-22-6704 8034	pravinmule@systematixgroup.in
Prathmesh Kamath	Oil & Gas, Logistics, Cement, Wagons	+91-22-6704 8022	prathmeshkamath@systematixgroup.in
Purvi Mundhra	Macro-Strategy	+91-22-6704 8078	purvimundhra@systematixgroup.in
Rajesh Mudaliar	Consumer Staples & Discretionary	+91-22-6704 8084	rajeshmudaliar@systematixgroup.in
Ronak Dhruv	NBFCs & Diversified Financials	+91-22-6704 8045	ronakdhruv@systematixgroup.in
Shweta Dikshit	Metals & Mining	+91-22-6704 8042	shwetadikshit@systematixgroup.in
Vivek Mane	Pharmaceuticals and Healthcare	+91-22-6704 8046	vivekmane@systematixgroup.in
Yogeeta Rathod	Midcaps	+91-22-6704 8081	yogeetarathod@systematixgroup.in
Equity Sales & Trading			
Name		Desk-Phone	E-mail
Vipul Sanghvi	Co Head of Equities & Head of Sales	+91-22-6704 8062	vipulsanghvi@systematixgroup.in
Jignesh Desai	Sales	+91-22-6704 8068	jigneshdesai@systematixgroup.in
Sidharth Agrawal	Sales	+91-22-6704 8090	sidharthagrawal@systematixgroup.in
Rahul Khandelwal	Sales	+91-22-6704 8003	rahul@systematixgroup.in
Chintan Shah	Sales	+91-22-6704 8061	chintanshah@systematixgroup.in
Pawan Sharma	Director and Head - Sales Trading	+91-22-6704 8067	pawansharma@systematixgroup.in
Mukesh Chaturvedi	Vice President and Co Head - Sales Trading	+91-22-6704 8074	mukeshchaturvedi@systematixgroup.in
Vinod Bhuwad	Sales Trading	+91-22-6704 8051	vinodbhuwad@systematixgroup.in
Rashmi Solanki	Sales Trading	+91-22-6704 8097	rashmisolanki@systematixgroup.in
Karan Damani	Sales Trading	+91-22-6704 8053	karandamani@systematixgroup.in
Vipul Chheda	Dealer	+91-22-6704 8087	vipulchheda@systematixgroup.in
Paras Shah	Dealer	+91-22-6704 8047	parasshah@systematixgroup.in
Rahul Singh	Dealer	+91-22-6704 8054	rahulsingh@systematixgroup.in
Corporate Access			
Mrunal Pawar	Vice President & Head Corporate Access	+91-22-6704 8088	mrunalpawar@systematixgroup.in
Darsha Hiwrale	Associate Corporate Access	+91-22-6704 8083	darshahiwrale@systematixgroup.in
Production			
Madhu Narayanan	Editor	+91-22-6704 8071	madhunarayanan@systematixgroup.in
Mrunali Pagdhare	Production	+91-22-6704 8057	mrunalip@systematixgroup.in
Vijayendra Achrekar	Production	+91-22-6704 8089	vijayendraachrekar@systematixgroup.ir
Operations	FIOUGERION	71-22-0704 0009	vijayenaraaciii ekar@systematixgroup.ii
	Vice President	±01_22_6704_90FF	cachinmalusara@quetamativarava :=
Sachin Malusare	Vice President	+91-22-6704 8055	sachinmalusare@systematixgroup.in
Jignesh Mistry	Manager	+91-22-6704 8049	jigneshmistry@systematixgroup.in
Sushant Chavan	Manager	+91-22-6704 8056	sushantchavan@systematixgroup.in

DISCLOSURES/APPENDIX

I. ANALYST CERTIFICATION

I, Pradeep Agrawal, Pravin Mule, Ronak Dhruv, hereby certify that (1) views expressed in this research report accurately reflect my/our personal views about any or all of the subject securities or issuers referred to in this research report, (2) no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by Systematix Shares and Stocks (India) Limited (SSSIL) or its group/associate companies, (3) reasonable care is taken to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

- II. ISSUER SPECIFIC REGULATORY DISCLOSURES, unless specifically mentioned in point no. 9 below:
 - 1. The research analyst(s), SSSIL, associates or relatives do not have any financial interest in the company(ies) covered in this report.
 - 2. The research analyst(s), SSSIL, associates or relatives collectively do not hold more than 1% of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
 - 3. The research analyst(s), SSSIL, associates or relatives did not have any other material conflict of interest at the time of publication of this research report.
 - 4. The research analyst, SSSIL and its associates have not received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in this report in the past twelve months.
 - 5. The research analyst, SSSIL or its associates have not managed or co-managed a private or public offering of securities for the company(ies) covered in this report in the previous twelve months.
 - 6. SSSIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party in connection with this research report.
 - 7. The research analyst has not served as an officer, director or employee of the company(ies) covered in this research report.
 - 8. The research analyst and SSSIL have not been engaged in market making activity for the company(ies) covered in this research report.
 - 9. Details of SSSIL, research analyst and its associates pertaining to the companies covered in this research report:

Sr. No.	Particulars	Yes / No.
1	Whether compensation was received from the company(ies) covered in the research report in the past 12 months for investment banking transaction by SSSIL.	No
2	Whether research analyst, SSSIL or its associates and relatives collectively hold more than 1% of the company(ies) covered in the research report.	No
3	Whether compensation has been received by SSSIL or its associates from the company(ies) covered in the research report.	No
4	Whether SSSIL or its affiliates have managed or co-managed a private or public offering of securities for the company(ies) covered in the research report in the previous twelve months.	No
5	Whether research analyst, SSSIL or associates have received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in the research report in the last twelve months.	No

10. There is no material disciplinary action taken by any regulatory authority that impacts the equity research analysis activities.

STOCK RATINGS

BUY (B): The stock's total return is expected to exceed 15% over the next 12 months.

HOLD (H): The stock's total return is expected to be within -15% to +15% over the next 12 months.

SELL (S): The stock's total return is expected to give negative returns of more than 15% over the next 12 months.

NOT RATED (NR): The analyst has no recommendation on the stock under review.

INDUSTRY VIEWS

ATTRACTIVE (AT): Fundamentals/valuations of the sector are expected to be attractive over the next 12-18 months.

NEUTRAL (NL): Fundamentals/valuations of the sector are expected to neither improve nor deteriorate over the next 12-18 months.

CAUTIOUS (CS): Fundamentals/valuations of the sector are expected to deteriorate over the next 12-18 months.

III. DISCLAIMER

The information and opinions contained herein have been compiled or arrived at based on the information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable; we do not represent that it is accurate or complete and one should exercise due caution while acting on it. Description of any company(ies) or its/their securities mentioned herein are not complete and this document is not and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments are also subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to SSSIL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United States (to U.S. persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed in Japan or to any resident thereof. Any unauthorized use, duplication,



redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the report is intended solely for the recipient and may not be further distributed by the recipient to any

SSSIL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, SSSIL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that they cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by SSSIL; however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of SSSIL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations which could have an adverse effect on their value or price or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk. SSSIL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on the basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SSSIL and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell, the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the company may or may not subscribe to the views expressed therein.

SSSIL, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall SSSIL, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The company accepts no liability whatsoever for the actions of third parties. The report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of the company, the company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the company shall be at your own risk and the company shall have no liability arising out of, or in connection with, any such referenced website.

SSSIL will not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall SSSIL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by SSSIL through this presentation.

SSSIL or any of its other group companies or associates will not be responsible for any decisions taken on the basis of this report. Investors are advised to consult their investment and tax consultants before taking any investment decisions based on this report.

Registration granted by SEBI to SSSIL and certification from NISM to the analyst in no way guarantee performance of SSSIL or to provide any assurance of returns to investors.





Systematix Shares and Stocks (India) Limited:

Registered and Corporate address: The Capital, A-wing, No. 603 – 606, 6th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Tel no. 022-66198000/40358000 Fax no. 022-66198029/40358029 Email id contactus@systematixgroup.in. Visit us at: www.systematixgroup.in

Details of Compliance officer: Ms Nipa Savla, Compliance officer Tel no. 022-66198092/4035808092 Email id compliance@systematixgroup.in

Details of Email id grievance redressal cell: grievance@systematixgroup.in

Details of Registration: CIN - U65993MH1995PLC268414 | BSE SEBI Reg. No.: INZ000171134 (Member Code: 182) | NSE SEBI Reg. No.: INZ000171134 (Member Code: 11327) | MCX SEBI Reg. No.: INZ000171134 (Member Code: 56625) | NCDEX SEBI Reg. No.: INZ000171134 (Member Code: 1281) | Depository Participant SEBI Reg. No.: IN-DP-480-2020 (DP Id: 12034600) | PMS SEBI Reg. No.: INP000002692 | Research Analyst SEBI Reg. No.: INH200000840 | AMFI: ARN - 64917